264 related articles for article (PubMed ID: 28461311)
1. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.
Torres BGS; Helfer VE; Bernardes PM; Macedo AJ; Nielsen EI; Friberg LE; Dalla Costa T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461311
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modeling of the influence of chronic and acute biofilm-forming Pseudomonas aeruginosa lung infection on ciprofloxacin free pulmonary and epithelial lining fluid concentrations.
Lock GA; Helfer VE; Dias BB; Torres BGS; De Araújo BV; Dalla Costa T
Eur J Pharm Sci; 2023 Oct; 189():106546. PubMed ID: 37517670
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
Zimmermann ES; de Miranda Silva C; Neris C; Torres BGDS; Schmidt S; Dalla Costa T
Eur J Pharm Sci; 2019 Jan; 127():319-329. PubMed ID: 30423435
[TBL] [Abstract][Full Text] [Related]
4. Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections.
Saini H; Chhibber S; Harjai K
Int J Antimicrob Agents; 2015 Apr; 45(4):359-67. PubMed ID: 25604277
[TBL] [Abstract][Full Text] [Related]
5. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro.
Bandara HM; Herpin MJ; Kolacny D; Harb A; Romanovicz D; Smyth HD
Mol Pharm; 2016 Aug; 13(8):2760-70. PubMed ID: 27383205
[TBL] [Abstract][Full Text] [Related]
7. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
[TBL] [Abstract][Full Text] [Related]
8. Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo.
Singh N; Romero M; Travanut A; Monteiro PF; Jordana-Lluch E; Hardie KR; Williams P; Alexander MR; Alexander C
Biomater Sci; 2019 Sep; 7(10):4099-4111. PubMed ID: 31355397
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms.
Tewes F; Bahamondez-Canas TF; Smyth HDC
AAPS PharmSciTech; 2019 May; 20(5):205. PubMed ID: 31144198
[TBL] [Abstract][Full Text] [Related]
10. Subinhibitory concentration of ciprofloxacin targets quorum sensing system of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence.
Gupta P; Chhibber S; Harjai K
Indian J Med Res; 2016 May; 143(5):643-51. PubMed ID: 27488009
[TBL] [Abstract][Full Text] [Related]
11. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis.
Patel KK; Tripathi M; Pandey N; Agrawal AK; Gade S; Anjum MM; Tilak R; Singh S
Int J Pharm; 2019 May; 563():30-42. PubMed ID: 30926526
[TBL] [Abstract][Full Text] [Related]
12. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model.
Owusu-Ababio G; Rogers JA; Morck DW; Olson ME
J Med Microbiol; 1995 Nov; 43(5):368-76. PubMed ID: 7563002
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.
Ahmed MN; Porse A; Sommer MOA; Høiby N; Ciofu O
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760140
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa.
Liu Z; Lin Y; Lu Q; Li F; Yu J; Wang Z; He Y; Song C
Infection; 2017 Feb; 45(1):23-31. PubMed ID: 27189338
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Lu Q; Yu J; Bao L; Ran T; Zhong H
Chemotherapy; 2013; 59(1):51-6. PubMed ID: 23816803
[TBL] [Abstract][Full Text] [Related]
17. Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Loo CY; Lee WH; Lauretani G; Scalia S; Cipolla D; Traini D; Young P; Ong HX
Pharm Res; 2018 Feb; 35(3):50. PubMed ID: 29417313
[TBL] [Abstract][Full Text] [Related]
18. Fostering Innovation in the Treatment of Chronic Polymicrobial Cystic Fibrosis-Associated Infections Exploring Aspartic Acid and Succinic Acid as Ciprofloxacin Adjuvants.
Silva E; Monteiro R; Grainha T; Alves D; Pereira MO; Sousa AM
Front Cell Infect Microbiol; 2020; 10():441. PubMed ID: 32974221
[TBL] [Abstract][Full Text] [Related]
19. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model.
Luo J; Dong B; Wang K; Cai S; Liu T; Cheng X; Lei D; Chen Y; Li Y; Kong J; Chen Y
PLoS One; 2017; 12(4):e0176883. PubMed ID: 28453568
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
